Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 5/30

$3.02+0.32 (+11.85%)

Close on Nov 13, 2026Market cap $313.73MP/E –Yield –

Larimar Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Larimar Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?